Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: A multicentre, prospective, randomised study

International Journal of Clinical Practice

Volumn 65, Issue 11, 2011, Pages 1193-1199

  Chung, M S ^a   Lee, S H ^a   Park, K K ^a   Yoo, S J ^a   Chung, B H ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DOXAZOSIN; HARNAL D; TAMSULOSIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHENIA; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEADACHE; HUMAN; INSOMNIA; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROGRADE EJACULATION; SYNCOPE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; DOXAZOSIN; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; SULFONAMIDES; TREATMENT OUTCOME;

EID: 80054687621     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02759.x     Document Type: Article

References (21)

1. Debruyne F, Jardin A, Colloi D, et al., Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 34: 169-75. (Pubitemid 28432911)
2. Fulton B, Wagstaff A, Sorkin E,. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995; 49: 295-320.
3. Debruyne FM,. Alpha blockers: are all created equal? Urology 2000; 56: 20-2.
4. Janknegt R, Chapple C,. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Eur Urol 1993; 24: 319-26. (Pubitemid 23306212)
5. Gillenwater JY, Conn RL, Chrysant SG, et al., Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo- controlled, dose-response multicenter study. J Urol 1995; 54: 110-5.
6. Fawzy A, Braun K, Lewis GP, et al., Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9.
7. Chapple C,. Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia. rationale and clinical experience. Eur Urol 1996; 29: 129-44. (Pubitemid 26059417)
8. Andersen M, Dahlstrand C, Hoye K,. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000; 38: 400-9.
9. Gratzke P, Kirby R,. Doxazosin GITS and doxazosin standard in patients with benign prostatic hyperplasia: double blind trial of efficacy and tolerability. Fortschr Med Orig 2000; 118 (Suppl 2): 83-92.
10. Chung M, Vashi V, Puente J, et al., Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999; 48: 678-87. (Pubitemid 29520591)
11. Kirby RS, Andersen M, Gratzke P, et al., A combined analysis of double-blind trials of the efficacy and tolerability of doxazosingastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200. (Pubitemid 32142527)
12. Abrams P, Schulman C, Vaage S,. Tamsulosin, a selective a1c-adrenoceptor antagonist: a randomized controlled trial in patients with benign prostatic ''obstruction'' (symptomatic BPH). Br J Urol 1995; 76: 325-36.
13. Chung BH, Park EK, Hong SJ,. The efficacy and safety of doxazosin GITS in patients with benign prostatic hyperplasia. Korean J Urol 2004; 45: 667-73.
14. Chung BH, Kim YS, Hong SJ,. 12-month follow-up study to evaluate the efficacy and safety of doxazosin GITS in patients with benign prostatic hyperplasia. Korean J Urol 2005; 46: 451-7. (Pubitemid 40790579)
15. Kirby RS,. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 2003; 91: 41-4.
16. Xue Z, Zhang Y, Ding Q, et al., Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients. Int J Urol 2007; 14: 118-22. (Pubitemid 46121948)
17. Pompeo AC, Rosenblatt C, Bertero E, et al., A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. Int J Clin Pract 2006; 60: 1172-7. Epub 2006 Aug 24. (Pubitemid 44363651)
18. Kirby RS, Quinn S, Mallen S, et al., Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. Int J Clin Pract 2004; 58: 6-10. (Pubitemid 38263226)
19. Kirby R, Andersson KE, Lepor H, et al., Alpha(1)-adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis 2000; 3: 76-83. (Pubitemid 30663592)
20. Cooper KL, McKiernan JM, Kaplan SA,. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs 1999; 57: 9-17. (Pubitemid 29042012)
21. Roehrborn CG, Schwinn DA,. Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004; 171: 1029-35. (Pubitemid 38327520)